Wang G, Ma G, Tao L, et al. - Researchers focused on 3-year results of the biodegradable polymer cobalt-chromium sirolimus-eluting stent (EXCROSSAL) in CREDIT II TRIAL (which represents a randomized trial contrasting the EXCROSSAL vs EXCEL stents in patients with up to two de novo coronary lesions) and in CREDIT III TRIAL (which signified a prospective, single-arm study assessing the efficacy and safety of EXCROSSAL in broad types of de novo coronary artery lesions). The 3-year follow-up data of the EXCROSSAL arm of both trials were pooled. The main outcome of interest was 3-year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularization. Overall 833 patients were included. Low rates of TLF and stent thrombosis in EXCROSSAL were corroborated, in the 3-year follow-up study, which is similar to the most extensively utilized new generation durable polymer drug-eluting stent.